XML 46 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVERSE MERGER (Narratives) (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 28, 2017
Jun. 29, 2017
Mar. 31, 2016
Sep. 30, 2017
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Business Combination Segment Allocation [Line Items]              
Shares converted, value   $ 3,000,000     $ 0 $ 433,000  
Common stock, shares outstanding (in shares)       9,446,878 9,446,878   449,175
Preferred stock, dividend rate (percentage)     8.00%        
Convertible Debt              
Business Combination Segment Allocation [Line Items]              
Debt instrument, face amount   800,000          
Private Placement              
Business Combination Segment Allocation [Line Items]              
Consideration received   400,000          
Transgenomics              
Business Combination Segment Allocation [Line Items]              
Conversion of debt into stock   $ 3,000,000          
Stock price used for estimating purchase consideration (in dollars per share)   $ 6.80          
Common stock, shares outstanding (in shares)   895,334          
Preferred stock, dividend rate (percentage)   8.00%          
Common Stock              
Business Combination Segment Allocation [Line Items]              
Number of shares converted (in shares) 1,735,419 7,356,170   943,600 943,600    
New shares issued (in shares)   200,081          
Common Stock | Precipio Diagnostic              
Business Combination Segment Allocation [Line Items]              
Number of shares converted (in shares)   5,352,847          
Common Stock | Transgenomics              
Business Combination Segment Allocation [Line Items]              
Number of shares converted from debt instrument (in shares)   352,630          
Preferred Stock              
Business Combination Segment Allocation [Line Items]              
Number of shares converted from debt instrument (in shares)   802,920          
Share price (in dollars per share)   $ 12.20          
Preferred Stock | Private Placement              
Business Combination Segment Allocation [Line Items]              
New shares issued (in shares)   107,056          
Preferred Stock | Transgenomics              
Business Combination Segment Allocation [Line Items]              
Number of shares converted (in shares)   7,155          
Number of shares converted from debt instrument (in shares)   802,925